Takeda Pharma (TKPYY) 22.6400 $TKPYY
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Natural Killer Cell Lymphomas Clinical Trials Review 2014
M2 - Tue Apr 29, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xct7cn/natural_killer) has announced the addition of the "Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" report to their offering. Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" provides data on the Natural Killer Cell Lymphomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Natural Killer Cell Lymphomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Natural Killer Cell Lymphomas. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Natural Killer Cell Lymphomas Therapeutics Clinical Trials - Kirin Holdings Company, Limited - Takeda Pharmaceutical Company Limited - Seattle Genetics, Inc. - Mundipharma International Limited - Cell Medica Limited - Fred Hutchinson Cancer Research Center - National Cancer Institute - Samsung Medical Center - Sun Yat-sen University - FUDAN University - University of Washington - Case Comprehensive Cancer Center - City of Hope National Medical Center - West China Hospital - NK-cell Tumor Study Group For more information visit http://www.researchandmarkets.com/research/xc...ral_killer
Global Leishmaniasis (Kala-Azar) Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pr5bk6/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Sanofi - Takeda Pharmaceutical Company Limited - Photopharmica Limited - Merck KGaA - iCo Therapeutics Inc. - Mologen AG - Advinus Therapeutics Ltd. - Dafra Pharma International Ltd. - aRigen Pharmaceuticals, Inc. - PolyTherics Limited Drug Profiles - pentoxifylline - fexinidazole - LEISH-F3 Vaccine - amphotericin B - MGN-1331 - Oleylphosphocholine - AS-605240 - Vaccine For Leishmania - amphotericin B NanoDisk - Small Molecules for Infectious Diseases - Small Molecule For Cutaneous Leishmaniasis - Small Molecule for Leishmaniasis - S-010269 - Compound-2d - VL-2098 - Compound-26g - pegylated amphotericin B - amphotericin b - Small Molecules For Leishmaniasis And Malaria - Isoxazole Containing Heteroretinoid And Amide Derivatives - Drug for Parasitic Diseases - Neglected Disease Program 2 - Small Molecules for Leishmaniasis and Oncology - methoxycoronaridine - Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - CDRI-99/288 - Nitroimidazole Backup Compound - Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Transfollicular Leishmaniasis Nanovaccine - ARA-03 For more information visit http://www.researchandmarkets.com/research/pr...shmaniasis
Teva to commercialise rasagiline for Parkinson's Disease in Japan in partnership with Takeda
M2 - Mon Apr 28, 4:47AM CDT
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA) reported on Friday the execution of an agreement to commercialise its innovative treatment for Parkinson's disease, rasagiline (active ingredient) in Japan.
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - Mon Apr 28, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory
Global Tetanus Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 29 Drug Profiles
M2 - Mon Apr 28, 2:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p5tm9w/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Panacea Biotec Limited - Bharat Biotech International Limited - Vaxin, Inc. - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - Act-HIB reconstituted with TRIPACEL - DTP-HepB-Polio-Hib - GC-1107 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - DTwP-HBV-Hib - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - Diphtheria Tetanus Pertussis Low Vaccine - Tetrabhay DTwP-H Vaccine - DTaP Vaccine - Adult Combinations TdaP Vaccine - TdaP Vaccine - Tetanus Vaccine - Diptheria And Tetanus Vaccine - Diptheria Tetanus And Pertussis Vaccine - DtwP-HB-Hib (liq) Vaccine - Tetanus Vaccine - GC-3111A - DTwP-IPV - LBVP-0101 - DTaP vaccine - Diphtheria Tetanus Acellular Pertussis Vaccine - Tetanus Vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib - DPT-H-HiB Vaccine For more information visit http://www.researchandmarkets.com/research/p5tm9w/tetanus
Wider-than-Expected Q1 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 10:00AM CDT
AMAG Pharmaceuticals Inc.'s (AMAG) first quarter 2014 loss of 33 cents per share was wider than the Zacks Consensus Estimate of a loss of 6 cents.
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
Pandemic Influenza - Pipeline Review, H1 2014 - Analysis of 33 Companies & 46 Drug Profiles
M2 - Wed Apr 23, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rtpnw/pandemic) has announced the addition of the "Pandemic Influenza - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Autoimmune Technologies, LLC - MedImmune, LLC - Emergent BioSolutions Inc. - Lentigen Corporation - Takeda Pharmaceutical Company Limited - Celltrion, Inc. - Novavax, Inc. - Vertex Pharmaceuticals Incorporated - Medicago Inc. - BioDiem Ltd - Adimmune Corporation - TechnoVax, Inc. - PDS Biotechnology Corporation - Theraclone Sciences, Inc. - Sinovac Biotech Ltd. - NanoBio Corporation - Protein Sciences Corporation - Immunovaccine, Inc. - VaxInnate Corporation - Immune Design Corp. - Sirnaomics, Inc. - VBI Vaccines - TSRL, Inc. - AltraVax Inc. - Big DNA Ltd. - PeptiVir, Inc. - Inhibikase Therapeutics, Inc. - Codagenix, Inc. - Medigen, Inc. For more information visit http://www.researchandmarkets.com/research/2rtpnw/pandemic
Latin America OTC Pharmaceuticals Market 2014-2018 with Bayer HealthCare AG., EMS S.A., Hypermarcas S.A., and Novartis AG Dominating
M2 - Wed Apr 16, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3ggp7m/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering. The OTC Pharmaceuticals Market in Latin America market to grow at a CAGR of 14% to 2018 One of the major drivers is the increasing switch from prescription to OTC drugs, which increases the number of OTC drugs available. The development and manufacture of drugs is a complex and time-consuming process, and it requires huge financial investments. As many vendors are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Certain vendors outsource different parts of the R&D process (such as product characterization testing and toxicology testing) to contract research organizations. Similarly, certain vendors are outsourcing part of their manufacturing process, or even the entire manufacturing process, to various organizations. Thus, outsourcing is one of the main trends in this market at present. Further, the report states that one of the major challenges in the market is the stringent regulations posed by regulatory bodies such as Ag?ncia Nacional de Vigil?ncia Sanit?ria, Brazil. Product recalls negatively affect a company's image, resulting in customers opting for other products available in the market, which leads to a fall in sales. Key vendors dominating this space include: - Bayer HealthCare AG. - EMS S.A. - Hypermarcas S.A. - Novartis AG. Other vendors mentioned in the report are: - Boehringer Ingelheim GmbH. - Genomma Lab Internacional SAB. - GlaxoSmithKline plc - Johnson & Johnson - Pfizer Inc - Takeda Pharmaceutical Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3ggp7m/otc
Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating
M2 - Mon Apr 14, 10:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh6tqs/global_depression) has announced the addition of the "Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating" report to their offering. Increasing public awareness regarding depression and associated disorders is expected to increase the acceptability of various drugs, and thereby an increase in drug penetration. For instance, ADAP educates high school students, teachers, and parents about depression disorder. ADAP aims to increase awareness about mood disorders in young people while stressing the need for evaluation and treatment. Similarly, the Peer-to-Peer Depression Awareness Campaign project is the student education component of the educational collaboration between the Depression Center and Ann Arbor public schools. The project aims to educate high school students about depression and depressive illnesses, and support them in finding creative ways to deliver this knowledge to their peers in order to reduce stigma, raise awareness, and help to promote the early detection of depression, bipolar disorder, and related illnesses. According to the report, one of the main drivers in this market is the increase in the number of patients suffering from depression. The increasing aging population is contributing to the growth of the market. The number of patients suffering from depression is increasing owing to increasingly elevated stress levels, unhealthy lifestyle, and social imbalances both in developing and developed nations. Further, the report states that one of the main challenges is the generic erosion of key blockbuster drugs. The introduction of low-priced generic drugs increases competition among vendors and reduces the cost of patented/branded drugs substantially. Key vendors dominating this space are - GlaxoSmithKline plc - Eli Lilly & Co. - Pfizer Inc - Forest Laboratories Inc. Other vendors mentioned in the report are - Astra Zeneca plc - Bristol Myers Squibb Co - Mallinckrodt Pharmaceuticals Inc. - Sanofi Aventis S.A. - Takeda Pharmaceutical Company Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Types - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Vendor Landscape - Key Vendor Analysis Visit http://www.researchandmarkets.com/research/gh...depression
Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
Seattle Genetics Earns Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:20PM CDT
Seattle Genetics has earned a milestone payment of $6 million from Takeda following the first commercial sales of Adcetris in key countries.
Global Smoking Cessation and Nicotine De-addiction Products Market 2013 - 2019
M2 - Wed Apr 09, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2qwff/smoking_cessation) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Electronic cigarettes is the largest and the fastest growing segment in the smoking cessation market. Smoking cessation or nicotine de-addiction can be achieved by various modes such as nicotine replacement products, e-cigarettes, anti-depressants and nicotine receptor agonists such as Zyban (bupropion), and Chantix/Champix (varenicline). Smoking de-addiction is also possible with or without assistance of healthcare professionals. The smoking cessation products market has been extensively analyzed on the basis of factors such as the products popularly used, success rate, and geographical reach. This report studies the global smoking cessation and nicotine de-addiction products market from the perspective of various product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. The NRT products market is broadly segmented into nicotine containing gums, transdermal patches, lozenges, sublingual tablets, sprays and nasal inhalers. The prominently used brands for smoking cessation are Zyban and Chantix/Champix which comprise the drug therapy segment of the market. Geographically, the market is analyzed for four major regions, namely North America, Europe, Asia Pacific and Rest of the World (RoW). Each of the segments have been analyzed on the basis of their current and future market size for the period 2011 to 2019, in terms of revenue (USD million), considering 2011 and 2012 as the base years. The compounded annual growth rate (% CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective shares in the smoking cessation and nicotine de-addiction products market for 2012 are provided in this report. Some of the major players profiled for NRT products include Johnson & Johnson, GSK, Pfizer, Takeda Pharmaceuticals Co. Ltd., Cipla, and Revolymer PLC. GSK and Pfizer lead the market for drug therapy while the key players profiled for e-cigarettes market include VMR products, and NJOY. Key Topics Covered: - Introduction - Executive Summary - Global Smoking Cessation and Nicotine De-addiction Market Overview - Global Smoking Cessation and Nicotine De-addiction Products Market, by Product Type - Global Smoking Cessation and Nicotine De-addiction Products Market, by Geography - Competitive Landscape - Recommendations - Company Profiles - Cipla Ltd. - GlaxoSmithKline, Inc. - Imperial Tobacco Company of India (ITC Ltd). - McNeil AB - NJOY, Inc. - Novartis International AG - Pfizer, Inc. - Revolymer PLC - Takeda Pharmaceutical Co. Ltd. - VMR Products LLC For more information visit http://www.researchandmarkets.com/research/x2..._cessation
Actos Bladder Cancer Lawsuit Update: Jury Awards $9 Billion in 1st MDL Actos Bladder Cancer Bellwether, One of the Largest Jury Awards in US History
PRWeb - Tue Apr 08, 6:32PM CDT
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, reports that Takeda Pharmaceutical Co. was ordered to pay $6 billion, and Eli Lilly & Co. was ordered to pay $3 billion, respectively, in consolidated Actos cases in Louisiana. (In Re Actos [Pioglitazone] Products Liability Litigation, 11-md-02299) According to an April 8, 2014 article in Bloomberg News, this $9 billion jury award is the seventh-largest in U.S. history based on data compiled by Bloomberg.
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co.
GlobeNewswire - Tue Apr 08, 11:52AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by portfolio company, Mersana Therapeutics, Inc., that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) to develop next-generation Fleximer(R) antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of the company's biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to Mersana's diverse, cytotoxic payloads.
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Natural Killer Cell Lymphomas Clinical Trials Review 2014
M2 - Tue Apr 29, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xct7cn/natural_killer) has announced the addition of the "Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" report to their offering. Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" provides data on the Natural Killer Cell Lymphomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Natural Killer Cell Lymphomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Natural Killer Cell Lymphomas. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Natural Killer Cell Lymphomas Therapeutics Clinical Trials - Kirin Holdings Company, Limited - Takeda Pharmaceutical Company Limited - Seattle Genetics, Inc. - Mundipharma International Limited - Cell Medica Limited - Fred Hutchinson Cancer Research Center - National Cancer Institute - Samsung Medical Center - Sun Yat-sen University - FUDAN University - University of Washington - Case Comprehensive Cancer Center - City of Hope National Medical Center - West China Hospital - NK-cell Tumor Study Group For more information visit http://www.researchandmarkets.com/research/xc...ral_killer
Global Leishmaniasis (Kala-Azar) Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pr5bk6/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Sanofi - Takeda Pharmaceutical Company Limited - Photopharmica Limited - Merck KGaA - iCo Therapeutics Inc. - Mologen AG - Advinus Therapeutics Ltd. - Dafra Pharma International Ltd. - aRigen Pharmaceuticals, Inc. - PolyTherics Limited Drug Profiles - pentoxifylline - fexinidazole - LEISH-F3 Vaccine - amphotericin B - MGN-1331 - Oleylphosphocholine - AS-605240 - Vaccine For Leishmania - amphotericin B NanoDisk - Small Molecules for Infectious Diseases - Small Molecule For Cutaneous Leishmaniasis - Small Molecule for Leishmaniasis - S-010269 - Compound-2d - VL-2098 - Compound-26g - pegylated amphotericin B - amphotericin b - Small Molecules For Leishmaniasis And Malaria - Isoxazole Containing Heteroretinoid And Amide Derivatives - Drug for Parasitic Diseases - Neglected Disease Program 2 - Small Molecules for Leishmaniasis and Oncology - methoxycoronaridine - Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - CDRI-99/288 - Nitroimidazole Backup Compound - Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis - Transfollicular Leishmaniasis Nanovaccine - ARA-03 For more information visit http://www.researchandmarkets.com/research/pr...shmaniasis
Teva to commercialise rasagiline for Parkinson's Disease in Japan in partnership with Takeda
M2 - Mon Apr 28, 4:47AM CDT
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA) reported on Friday the execution of an agreement to commercialise its innovative treatment for Parkinson's disease, rasagiline (active ingredient) in Japan.
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trials Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/94xvzp/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Johnson & Johnson - Sanofi - Novartis AG - AstraZeneca PLC - Astellas Pharma Inc. - Medivation, Inc. - Dendreon Corporation - Takeda Pharmaceutical Company Limited - Exelixis, Inc. - Bristol-Myers Squibb Company - National Cancer Institute - Duke University - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Swiss Group for Clinical Cancer Research - Barbara Ann Karmanos Cancer Institute - NCIC Clinical Trials Group - Memorial Sloan Kettering Cancer Center - University of Southern California For more information visit http://www.researchandmarkets.com/research/94xvzp/metastatic
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Global Refractory Multiple Myeloma Global Clinical Trials Review 2014
M2 - Mon Apr 28, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gphksg/refractory) has announced the addition of the "Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" report to their offering. Refractory Multiple Myeloma Global Clinical Trials Review, H1, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Profiles of Top Companies/Organisations - Celgene Corporation - Amgen Inc. - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Novartis AG - Merck & Co., Inc. - F. Hoffmann-La Roche Ltd. - Pfizer Inc. - Bristol-Myers Squibb Company - AbbVie Inc. - National Cancer Institute - Fred Hutchinson Cancer Research Center - Mayo Clinic - The University of Texas M. D. Anderson Cancer Center - University of Arkansas - Case Comprehensive Cancer Center - Memorial Sloan Kettering Cancer Center - City of Hope National Medical Center - Washington University School of Medicinea For more information visit http://www.researchandmarkets.com/research/gphksg/refractory
Global Tetanus Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 29 Drug Profiles
M2 - Mon Apr 28, 2:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p5tm9w/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Panacea Biotec Limited - Bharat Biotech International Limited - Vaxin, Inc. - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - Act-HIB reconstituted with TRIPACEL - DTP-HepB-Polio-Hib - GC-1107 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - DTwP-HBV-Hib - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - Diphtheria Tetanus Pertussis Low Vaccine - Tetrabhay DTwP-H Vaccine - DTaP Vaccine - Adult Combinations TdaP Vaccine - TdaP Vaccine - Tetanus Vaccine - Diptheria And Tetanus Vaccine - Diptheria Tetanus And Pertussis Vaccine - DtwP-HB-Hib (liq) Vaccine - Tetanus Vaccine - GC-3111A - DTwP-IPV - LBVP-0101 - DTaP vaccine - Diphtheria Tetanus Acellular Pertussis Vaccine - Tetanus Vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib - DPT-H-HiB Vaccine For more information visit http://www.researchandmarkets.com/research/p5tm9w/tetanus
Wider-than-Expected Q1 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 10:00AM CDT
AMAG Pharmaceuticals Inc.'s (AMAG) first quarter 2014 loss of 33 cents per share was wider than the Zacks Consensus Estimate of a loss of 6 cents.
Global Mycosis Fungoides Global Clinical Trials Review 2014
M2 - Fri Apr 25, 8:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l6stqf/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides Global Clinical Trials Review, H1, 2014" report to their offering. Mycosis Fungoides Global Clinical Trials Review, H1, 2014" provides data on the Mycosis Fungoides clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mycosis Fungoides. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mycosis Fungoides. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Mycosis Fungoides Therapeutics Clinical Trials - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - Eisai Co., Ltd. - Actelion Ltd - Janssen Global Services, LLC - Emergent BioSolutions Inc. - Echo Therapeutics, Inc. - Angimmune LLC Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - Northwestern University - University of Washington - Stanford University - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - Barbara Ann Karmanos Cancer Institute - Wake Forest University For more information visit http://www.researchandmarkets.com/research/l6..._fungoides
Global Hypertension Drugs Market 2014-2018 with Actelion, AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Sanofi Dominating
M2 - Thu Apr 24, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/brq49m/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market is driven by several factors, of which an increase in aging population is one of the major drivers. There is a natural tendency for BP to rise with age due to the reduced elasticity of the arterial system. The promising hypertension drug pipeline is another major driver. The clinical pipeline for hypertension drugs is moderately strong with more emerging therapies. The Global Hypertension Drugs market is experiencing a shift toward combination products, using two or more combination treatments. A combination of hypertension therapy with separate agents or a fixed-dose combination pill lowers BP at a faster pace, helps in reaching the target BP, and decreases adverse effects. Additional benefits may include cost savings and better compliance. Moreover, antihypertensive agents from different classes may balance adverse reactions from each other. For instance, for hypertensive patients with diabetes, the recommended treatment includes diuretics, beta blockers, ACE inhibitors, ARBs, and/or CCBs. The Joint National Committee guidelines have recommended diuretics and ACE inhibitors for recurrent stroke prevention in patients with hypertension; beta blockers, ACE inhibitors, and aldosterone antagonists for hypertensive patients who are post myocardial infarction; and ACE inhibitors and ARBs for hypertensive patients with chronic kidney disease. Further, the report states that the increasing number of patent expirations is one of the main challenges. The patent expiries of major approved drugs will slow down the market growth, as the shift toward lower-priced drugs will lead to a drop in the market valuation for that drug, thereby reducing the overall market value. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/brq49m/global
Pandemic Influenza - Pipeline Review, H1 2014 - Analysis of 33 Companies & 46 Drug Profiles
M2 - Wed Apr 23, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rtpnw/pandemic) has announced the addition of the "Pandemic Influenza - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Baxter International Inc. - Autoimmune Technologies, LLC - MedImmune, LLC - Emergent BioSolutions Inc. - Lentigen Corporation - Takeda Pharmaceutical Company Limited - Celltrion, Inc. - Novavax, Inc. - Vertex Pharmaceuticals Incorporated - Medicago Inc. - BioDiem Ltd - Adimmune Corporation - TechnoVax, Inc. - PDS Biotechnology Corporation - Theraclone Sciences, Inc. - Sinovac Biotech Ltd. - NanoBio Corporation - Protein Sciences Corporation - Immunovaccine, Inc. - VaxInnate Corporation - Immune Design Corp. - Sirnaomics, Inc. - VBI Vaccines - TSRL, Inc. - AltraVax Inc. - Big DNA Ltd. - PeptiVir, Inc. - Inhibikase Therapeutics, Inc. - Codagenix, Inc. - Medigen, Inc. For more information visit http://www.researchandmarkets.com/research/2rtpnw/pandemic
Latin America OTC Pharmaceuticals Market 2014-2018 with Bayer HealthCare AG., EMS S.A., Hypermarcas S.A., and Novartis AG Dominating
M2 - Wed Apr 16, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3ggp7m/otc) has announced the addition of the "OTC Pharmaceuticals Market in Latin America 2014-2018" report to their offering. The OTC Pharmaceuticals Market in Latin America market to grow at a CAGR of 14% to 2018 One of the major drivers is the increasing switch from prescription to OTC drugs, which increases the number of OTC drugs available. The development and manufacture of drugs is a complex and time-consuming process, and it requires huge financial investments. As many vendors are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Certain vendors outsource different parts of the R&D process (such as product characterization testing and toxicology testing) to contract research organizations. Similarly, certain vendors are outsourcing part of their manufacturing process, or even the entire manufacturing process, to various organizations. Thus, outsourcing is one of the main trends in this market at present. Further, the report states that one of the major challenges in the market is the stringent regulations posed by regulatory bodies such as Ag?ncia Nacional de Vigil?ncia Sanit?ria, Brazil. Product recalls negatively affect a company's image, resulting in customers opting for other products available in the market, which leads to a fall in sales. Key vendors dominating this space include: - Bayer HealthCare AG. - EMS S.A. - Hypermarcas S.A. - Novartis AG. Other vendors mentioned in the report are: - Boehringer Ingelheim GmbH. - Genomma Lab Internacional SAB. - GlaxoSmithKline plc - Johnson & Johnson - Pfizer Inc - Takeda Pharmaceutical Co. Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Products - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3ggp7m/otc
Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating
M2 - Mon Apr 14, 10:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gh6tqs/global_depression) has announced the addition of the "Global Depression Drugs Market 2014-2018 with GlaxoSmithKline plc, Eli Lilly & Co., Pfizer Inc., and Forest Laboratories Dominating" report to their offering. Increasing public awareness regarding depression and associated disorders is expected to increase the acceptability of various drugs, and thereby an increase in drug penetration. For instance, ADAP educates high school students, teachers, and parents about depression disorder. ADAP aims to increase awareness about mood disorders in young people while stressing the need for evaluation and treatment. Similarly, the Peer-to-Peer Depression Awareness Campaign project is the student education component of the educational collaboration between the Depression Center and Ann Arbor public schools. The project aims to educate high school students about depression and depressive illnesses, and support them in finding creative ways to deliver this knowledge to their peers in order to reduce stigma, raise awareness, and help to promote the early detection of depression, bipolar disorder, and related illnesses. According to the report, one of the main drivers in this market is the increase in the number of patients suffering from depression. The increasing aging population is contributing to the growth of the market. The number of patients suffering from depression is increasing owing to increasingly elevated stress levels, unhealthy lifestyle, and social imbalances both in developing and developed nations. Further, the report states that one of the main challenges is the generic erosion of key blockbuster drugs. The introduction of low-priced generic drugs increases competition among vendors and reduces the cost of patented/branded drugs substantially. Key vendors dominating this space are - GlaxoSmithKline plc - Eli Lilly & Co. - Pfizer Inc - Forest Laboratories Inc. Other vendors mentioned in the report are - Astra Zeneca plc - Bristol Myers Squibb Co - Mallinckrodt Pharmaceuticals Inc. - Sanofi Aventis S.A. - Takeda Pharmaceutical Company Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Types - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Rate of Incidence and Prevalence - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Vendor Landscape - Key Vendor Analysis Visit http://www.researchandmarkets.com/research/gh...depression
Global B-Cell Non-Hodgkin Lymphoma Clinical Trials Review
M2 - Thu Apr 10, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6w5nm9/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - F. Hoffmann-La Roche Ltd. - Celgene Corporation - Takeda Pharmaceutical Company Limited - GlaxoSmithKline plc - Amgen Inc. - Novartis AG - Pharmacyclics, Inc. - Pfizer Inc. - Biogen Idec Inc. - Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Mayo Clinic - Southwest Oncology Group - Groupe d'Etudes de Lymphomes de L'Adulte - City of Hope National Medical Center - Stanford University For more information visit http://www.researchandmarkets.com/research/6w5nm9/bcell
Seattle Genetics Earns Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:20PM CDT
Seattle Genetics has earned a milestone payment of $6 million from Takeda following the first commercial sales of Adcetris in key countries.
Global Smoking Cessation and Nicotine De-addiction Products Market 2013 - 2019
M2 - Wed Apr 09, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2qwff/smoking_cessation) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Electronic cigarettes is the largest and the fastest growing segment in the smoking cessation market. Smoking cessation or nicotine de-addiction can be achieved by various modes such as nicotine replacement products, e-cigarettes, anti-depressants and nicotine receptor agonists such as Zyban (bupropion), and Chantix/Champix (varenicline). Smoking de-addiction is also possible with or without assistance of healthcare professionals. The smoking cessation products market has been extensively analyzed on the basis of factors such as the products popularly used, success rate, and geographical reach. This report studies the global smoking cessation and nicotine de-addiction products market from the perspective of various product types available in the market. These include nicotine replacement therapy (NRT) products, drug therapy and e-cigarettes. The NRT products market is broadly segmented into nicotine containing gums, transdermal patches, lozenges, sublingual tablets, sprays and nasal inhalers. The prominently used brands for smoking cessation are Zyban and Chantix/Champix which comprise the drug therapy segment of the market. Geographically, the market is analyzed for four major regions, namely North America, Europe, Asia Pacific and Rest of the World (RoW). Each of the segments have been analyzed on the basis of their current and future market size for the period 2011 to 2019, in terms of revenue (USD million), considering 2011 and 2012 as the base years. The compounded annual growth rate (% CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective shares in the smoking cessation and nicotine de-addiction products market for 2012 are provided in this report. Some of the major players profiled for NRT products include Johnson & Johnson, GSK, Pfizer, Takeda Pharmaceuticals Co. Ltd., Cipla, and Revolymer PLC. GSK and Pfizer lead the market for drug therapy while the key players profiled for e-cigarettes market include VMR products, and NJOY. Key Topics Covered: - Introduction - Executive Summary - Global Smoking Cessation and Nicotine De-addiction Market Overview - Global Smoking Cessation and Nicotine De-addiction Products Market, by Product Type - Global Smoking Cessation and Nicotine De-addiction Products Market, by Geography - Competitive Landscape - Recommendations - Company Profiles - Cipla Ltd. - GlaxoSmithKline, Inc. - Imperial Tobacco Company of India (ITC Ltd). - McNeil AB - NJOY, Inc. - Novartis International AG - Pfizer, Inc. - Revolymer PLC - Takeda Pharmaceutical Co. Ltd. - VMR Products LLC For more information visit http://www.researchandmarkets.com/research/x2..._cessation
Actos Bladder Cancer Lawsuit Update: Jury Awards $9 Billion in 1st MDL Actos Bladder Cancer Bellwether, One of the Largest Jury Awards in US History
PRWeb - Tue Apr 08, 6:32PM CDT
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, reports that Takeda Pharmaceutical Co. was ordered to pay $6 billion, and Eli Lilly & Co. was ordered to pay $3 billion, respectively, in consolidated Actos cases in Louisiana. (In Re Actos [Pioglitazone] Products Liability Litigation, 11-md-02299) According to an April 8, 2014 article in Bloomberg News, this $9 billion jury award is the seventh-largest in U.S. history based on data compiled by Bloomberg.
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co.
GlobeNewswire - Tue Apr 08, 11:52AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by portfolio company, Mersana Therapeutics, Inc., that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) to develop next-generation Fleximer(R) antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of the company's biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to Mersana's diverse, cytotoxic payloads.
